Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.

Next Previous
X
Search
Trial Profile

Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Squalamine (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Ohr Pharmaceutical

    • Most Recent Events

    • 10 May 2016 Results of analysis of lesion characteristics as predictors of visual outcome were presented at the Association for Research in Vision and Ophthalmology (ARVO) Conference 2016, according to an Ohr Pharmaceutical media release.
    • 16 Nov 2015 According to an Ohr Pharmaceuticals media release, additional data from this trial has been presented at the annual meeting of the American Academy of Ophthalmology (AAO).
    • 16 Nov 2015 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top